De novo depression and anxiety disorders and influence on adherence during peginterferon‐alpha‐2a and ribavirin treatment in patients with hepatitis C
Open Access
- 6 November 2007
- journal article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 27 (3) , 257-265
Abstract
Summary: Background Depression and anxiety have been associated with interferon treatment and low treatment adherence.Aim To study the incidence and associated risk factors of depressive and anxiety disorders during pegylated interferon plus ribavirin and treatment adherence in a prospective cohort of 176 patients with chronic hepatitis C patients.Methods Patients were interviewed at baseline using the Structured Clinical Interview for DSM‐IV Mental Disorders and the Patient Health Questionnaire and the Hospital Anxiety and Depression Scale were completed. Both questionnaires were completed also after 4, 12 and 24 weeks of treatment.Results De novo depressive and/or anxiety disorders were diagnosed in 53 (36%) patients, in whom antidepressants and/or anxiolytics were administered. Higher baseline depression‐subscale score (OR = 27.8, 95% CI = 2.82–333), primary education level (OR = 3.1, 95% CI = 1.40–7.03) and being an immigrant (OR = 3.2, 95% CI = 1.12–9.47) were predictors of psychiatric disorders during anti‐viral therapy. The percentage of patients with good adherence was lower in those with depression and/or anxiety (79% vs. 90%, P < 0.04). Only one patient (1%) discontinued treatment because of a major depressive episode. Depression and/or anxiety disorders had no effect on attainment of sustained virological response.Conclusion Early detection and treatment of depressive and anxiety disorders favours good adherence to anti‐viral treatment in hepatitis C.Keywords
This publication has 41 references indexed in Scilit:
- A randomized trial of paroxetine to prevent interferon-α-induced depression in patients with hepatitis CJournal of Affective Disorders, 2007
- Paroxetine for prevention of depressive symptoms induced by interferon‐alpha and ribavirin for hepatitis CAlimentary Pharmacology & Therapeutics, 2007
- Depression and anxiety in patients with hepatitis C: prevalence, detection rates and risk factorsGeneral Hospital Psychiatry, 2005
- Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis CJournal of Hepatology, 2005
- Psychopharmacological Treatment of Depression, Anxiety, Irritability and Insomnia in Patients Receiving Interferon-α: a Prospective Case Series and a Discussion of Biological MechanismsJournal of Psychopharmacology, 2004
- Hepatocellular CarcinomaJournal of Clinical Gastroenterology, 2002
- Paroxetine for the Prevention of Depression Induced by High-Dose Interferon AlfaNew England Journal of Medicine, 2001
- The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994New England Journal of Medicine, 1999
- INTERFERONS AS MEDIATORS OF PSYCHIATRIC MORBIDITYThe Lancet, 1987
- The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica, 1983